SPHS
Sophiris Bio, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.
Market Cap: 7.93 Million
Primary Exchange: NASDAQ
Website: http://www.sophirisbio.com
Shares Outstanding: 34.5 Million
Float: 34.4 Million
Dividend: (%)
Beta: 1.8329836910552295
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 927 trading days
From: 2016-07-25 To: 2020-03-11
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|